Selection bias of elderly patients with chronic angina referred for catheterization

Int J Cardiol. 2006 Jun 7;110(1):80-5. doi: 10.1016/j.ijcard.2005.07.024. Epub 2005 Oct 12.

Abstract

Background: Registry patients are generally older and more sick than patients enrolled in trials questioning the generalizability of trial results. We assessed whether such a selection bias also exists in elderly patients with chronic angina referred for catheterization.

Methods and results: All 119 patients age>or=75 years with Trial of Invasive versus Medical Therapy in the Elderly (TIME) inclusion but no major exclusion criteria referred for catheterization during the TIME trial inclusion period in four TIME centers were registered and followed-up for one year. Registry patients differed from the 188 trial patients in the same hospitals in that they were younger, somewhat more frequently male, with less antianginal drugs and studied more often after acute chest pain at rest but with more comorbidities than study patients. Left ventricular ejection fraction and vessel disease were similar. One year mortality was 11.4% in registry and 9.6% in invasive TIME patients but differences disappeared after adjustment for baseline differences. Symptomatic status after one year was similar too.

Conclusions: In elderly patients with chronic angina, a bias in the selection for invasive management exists which seems different from that reported in younger patient settings. After adjustment for these selection factors, however, one-year outcome was remarkably similar in registry and trial patients.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Angina Pectoris / mortality
  • Angina Pectoris / therapy*
  • Cardiac Catheterization
  • Cardiovascular Agents / therapeutic use
  • Chronic Disease
  • Coronary Angiography
  • Coronary Artery Disease / mortality
  • Coronary Artery Disease / therapy
  • Female
  • Humans
  • Male
  • Myocardial Revascularization*
  • Quality of Life*
  • Risk Assessment
  • Selection Bias*
  • Survival Rate
  • Treatment Outcome

Substances

  • Cardiovascular Agents